Daily Sepsis Research Analysis
Analyzed 25 papers and selected 3 impactful papers.
Summary
Three impactful studies span surveillance, therapeutics, and hemodynamics in sepsis. A multiregional JAMA Pediatrics analysis forecasts rising pediatric resistance—especially among Gram-negatives causing sepsis—threatening empiric therapy by 2035. Preclinically, a dual IDO1/NE inhibitor (IMM-H018) curbed cytokine storm, microthrombosis, and immunosuppression in murine sepsis, while a MIMIC-IV cohort linked early milrinone exposure to lower 28-day mortality, particularly in patients with heart failure.
Research Themes
- Global pediatric antimicrobial resistance trajectories and forecasting for empiric therapy
- Dual-target immuno-thromboinflammatory modulation in sepsis (IDO1/NE inhibition)
- Hemodynamic pharmacotherapy in sepsis: phosphodiesterase-3 inhibition and outcomes
Selected Articles
1. Childhood Antimicrobial Resistance With Global Forecasts.
Using 106,581 pediatric isolates from 82 countries (2004–2022), this surveillance study shows rising antimicrobial resistance across regions, with the fastest increases in ICUs, in children aged 0–2 years, and among sepsis and respiratory infection cases. Projections to 2035 indicate carbapenem resistance reaching 35% in Klebsiella spp and 82% in Acinetobacter baumannii, jeopardizing empiric therapy for severe pediatric infections.
Impact: Provides robust, globally representative resistance trajectories with forecasts to 2035, directly informing empiric antibiotic choices for pediatric sepsis and pneumonia.
Clinical Implications: Update empiric therapy pathways by geography, ICU setting, and age; prioritize coverage for rising Gram-negative resistance; strengthen stewardship and surveillance where Watch/Reserve resistance is accelerating.
Key Findings
- Pediatric AMR increased globally from 2004–2022, with the fastest growth in ICUs, children aged 0–2 years, and in sepsis and respiratory infections.
- Resistance to Access agents is stabilizing, whereas Watch and Reserve resistance continues to rise, especially in Gram-negative pathogens.
- By 2035, projected carbapenem resistance is 35% in Klebsiella spp and 82% in Acinetobacter baumannii; A. baumannii exceeded 55% resistance across all AWaRe categories during the study.
Methodological Strengths
- Large, multiregional dataset (106,581 pediatric isolates) with standardized AWaRe categorization
- Advanced spatiotemporal modeling to forecast resistance through 2035 with uncertainty intervals
Limitations
- Surveillance isolates may not fully represent all clinical infections or care settings, especially in resource-limited regions
- Lack of direct linkage to patient-level outcomes or antibiotic exposure data limits causal inference for treatment effectiveness
Future Directions: Integrate patient-level outcomes and antimicrobial exposure; refine geospatial empiric therapy guidance; evaluate stewardship and vaccine interventions targeting high-risk Gram-negative trajectories.
IMPORTANCE: Antimicrobial resistance (AMR) threatens effective treatment of severe childhood infections, but multiregional data about pediatric AMR remain limited. OBJECTIVE: To assess geographic and temporal AMR trends among children for World Health Organization (WHO) priority pathogens using the WHO Access, Watch, and Reserve (AWaRe) antibiotic classification. DESIGN, SETTING, AND PARTICIPANTS: This multiregional surveillance study analyzed pediatric bacterial isolates from the Antimicrobial Testing Leadership and Surveillance (ATLAS) database between January 2004 and December 2022. The analysis included 106 581 isolates from 106 581 children aged 0 to 18 years in 82 countries. Data were analyzed from February 2024 to April 2026. EXPOSURES: Resistance to AWaRe-categorized antibiotics in WHO priority bacterial pathogens. MAIN OUTCOMES AND MEASURES: Temporal trends in resistance were evaluated using linear and nonlinear models, by geographic region, age, setting, and infection. Spatiotemporal generalized additive models were applied to estimate resistance trajectories and forecast to 2035. RESULTS: Of 106 581 children included in this study, 47% were aged 0 to 2 years, 35% were aged 3 to 12 years, and 18% were aged 13 to 18 years; 58 620 (55%) were male. From 2004 to 2022, pediatric AMR increased in all regions, with consistently higher resistance levels and faster growth in resource-limited settings. Resistance to any Access-group antibiotic was highest overall at a mean of 36% (range, 2%-66%), with resistance to Watch-group antibiotics at a mean of 22% (range, 1%-47%) and Reserve-group antibiotics at a mean of 13% (range, 0%-30%). Resistance to antibiotics in the Watch and Reserve groups increased most rapidly in intensive care units, wherein Watch-group antibiotic resistance increased from 15% (517/3564) to 33% (2910/8748) (P < .001), especially in those aged 0 to 2 years (12% [325/2649] to 32% [1257/3959]; P < .001) and those with sepsis (15% [298/2030] to 30% [1409/4705]; P < .001) and respiratory infections [12% [657/5324] to 29% [3311/11507]; P < .001). Acinetobacter baumannii had the highest overall resistance (more than 55% in every AWaRe category), while Klebsiella species increased fastest, particularly to third- or fourth-generation cephalosporins and carbapenems in Southeast Asia, Eastern Europe, and the Western Pacific. Projections suggested stabilization of resistance to Access antibiotics but continued increases in resistance to antibiotics in the Watch and Reserve groups, especially in Gram-negative pathogens. By 2035, carbapenem resistance was projected to be 35% (95% uncertainty interval [UI], 29%-40%) in Klebsiella species and 82% (95% UI, 77%-85%) in A baumannii. CONCLUSIONS AND RELEVANCE: Pediatric AMR increased in all regions across the study period, driven primarily by escalating resistance among Gram-negative pathogens responsible for sepsis and pneumonia. These trends threaten the effectiveness of empiric therapy for severe childhood infections, particularly in settings with limited alternative treatment options.
2. A Novel IDO1/NE Dual Inhibitor, IMM-H018 Prevents the Primary and Secondary Sepsis and Ameliorates the Kidney Injury Through Inhibiting the Cytokine Storm and Microthrombosis, and Reversing Immunosuppression.
IMM-H018, a first-in-class dual IDO1/neutrophil elastase inhibitor, suppressed cytokine storm, reversed immune dysfunction, reduced renal microthrombosis via the IDO1–kynurenine–AhR–tissue factor pathway, and improved survival in murine sepsis. It outperformed combined epacadostat plus sivelestat, also preventing secondary infection and enhancing phagocytosis in a two-hit model.
Impact: Demonstrates a mechanistically coherent, dual-target approach that addresses inflammation, coagulopathy, and immunosuppression—the triad central to sepsis pathobiology—showing superior efficacy to combination monotherapy.
Clinical Implications: Supports clinical translation of dual-pathway inhibitors in sepsis; suggests biomarker-guided development (kynurenine, NE activity) and potential benefit in preventing secondary infections and sepsis-associated acute kidney injury.
Key Findings
- IMM-H018 inhibited both IDO1 and neutrophil elastase in vitro and in vivo and significantly improved survival in CLP-induced sepsis.
- Reduced systemic inflammation and restored immune function in blood, thymus, and spleen, outperforming epacadostat plus sivelestat.
- Mitigated sepsis-associated AKI by improving renal perfusion and reducing microthrombosis via the IDO1–kynurenine–AhR–tissue factor pathway; prevented secondary infection and enhanced phagocytosis in a two-hit model.
Methodological Strengths
- Multiple complementary in vivo sepsis models (LPS, CLP, two-hit) with mechanistic pathway validation
- Head-to-head comparison against combination of single-target inhibitors
Limitations
- Preclinical animal study; human pharmacokinetics, safety, and dose-response are unknown
- Potential off-target effects and scalability require further toxicology and translational studies
Future Directions: Conduct GLP toxicology, PK/PD, and biomarker-driven phase 1/2 trials; explore patient selection by immune-coagulopathy phenotypes and monitor kynurenine and NE activity as pharmacodynamic markers.
Sepsis is characterized by the simultaneous presence of hyperinflammation, immunosuppression, and coagulation abnormalities, making single-target therapies insufficient. In this study, we explored a strategy that concurrently suppresses neutrophil-mediated inflammation and reverses immune dysfunction. Combined treatment with the neutrophil elastase (NE) inhibitor Sivelestat and the indoleamine 2,3-dioxygenase-1 (IDO1) inhibitor Epacadostat showed superior efficacy to either monotherapy in LPS- and CLP-induced septic mice. Based on this concept, a novel dual IDO1/NE inhibitor, IMM-H018, was designed and synthesized. IMM-H018 effectively inhibited both IDO1 and NE activities in vitro and in vivo and significantly improved survival in CLP-induced sepsis. In low-dose LPS models, IMM-H018 reduced systemic inflammation and restored immune function in peripheral blood, thymus, and spleen, outperforming the combination therapy. Furthermore, IMM-H018 alleviated sepsis-associated acute kidney injury by improving renal perfusion and reducing microthrombosis through inhibition of the IDO1-Kyn-AhR-TF pathway. In a two-hit sepsis model, IMM-H018 prevented secondary infection, enhanced bacterial clearance through improved phagocytosis, protected against renal damage, and delayed progression from acute kidney injury to chronic kidney dysfunction. These findings identify IMM-H018 as a promising therapeutic candidate for sepsis and sepsis-associated kidney injury.
3. Association between Milrinone Use and Mortality Risk in Sepsis: Insights from the MIMIC-IV Database.
In a 27,070-patient MIMIC-IV cohort, early milrinone exposure was associated with lower 28-day mortality after adjustment, with TMLE supporting protective effects at 14 and 28 days. Dose-response was linear for 7-day mortality and nonlinear thereafter; benefits were concentrated in patients with heart failure.
Impact: Suggests a pragmatic hemodynamic strategy in septic patients—particularly with heart failure—that merits prospective evaluation, using modern causal inference methods to mitigate confounding.
Clinical Implications: Consider milrinone as an adjunct in septic patients with concomitant heart failure while awaiting prospective trials; monitor dose-response and hemodynamics closely to avoid potential threshold-related harms.
Key Findings
- Among 27,070 septic patients, milrinone exposure (n=523) was associated with reduced 28-day mortality after IPTW adjustment; TMLE supported protective effects at 14 and 28 days.
- Restricted cubic spline analyses showed a linear inverse association between cumulative dose and 7-day mortality, with nonlinear relationships at 14 and 28 days.
- Subgroup analysis revealed mortality reduction predominantly in patients with heart failure, indicating effect modification by cardiac comorbidity.
Methodological Strengths
- Large ICU cohort with multiple causal inference techniques (PSM, IPTW, TMLE) and dose–response modeling (RCS)
- Early drug exposure timing captured (median 5.24 hours post-ICU admission)
Limitations
- Retrospective observational design with potential residual confounding and confounding by indication
- Generalizability limited to a single database; lack of randomized allocation or protocolized hemodynamic targets
Future Directions: Prospective, randomized evaluation of milrinone in septic patients—enriched for heart failure—integrating hemodynamic phenotyping and safety endpoints to define optimal dosing and thresholds.
BACKGROUND: Milrinone is established in the management of heart failure. However, its therapeutic role in patients with sepsis remains uncertain and warrants further investigation. Objective: To examine the association between milrinone administration and mortality in patients diagnosed with sepsis. METHODS: This retrospective cohort study utilized data from the MIMIC-IV database. The primary exposure of interest was milrinone use. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were employed to balance baseline characteristics. The association between milrinone use and 7-，14-，and 28-day mortality in sepsis patients was assessed using multivariate Cox proportional hazards models, restricted cubic spline (RCS) curves, and longitudinal targeted maximum likelihood estimation (TMLE). RESULTS: Among 27,070 sepsis patients, 523 received milrinone at a median interval of 5.24 hours after ICU admission. In the unadjusted Cox model, milrinone use was associated with significantly lower mortality at 7 days (HR = 0.53, 95% CI: 0.33-0.85), 14 days (HR = 0.54, 95% CI: 0.38-0.78), and 28 days (HR = 0.60, 95% CI: 0.45-0.82). This association remained consistent after adjusting for multiple confounders. In the IPTW-adjusted cohort, Cox regression showed no significant association between milrinone use and mortality at day 7 or day 14; however, a statistically significant association was observed at day 28. Longitudinal TMLE analyses further indicated a protective effect for both 14-day (RR = 0.65, 95% CI: 0.48-0.88; P = 0.01) and 28-day mortality (RR = 0.58, 95% CI: 0.45-0.74; P < 0.001). RCS analysis demonstrated a linear inverse relationship between cumulative milrinone dosage and 7-day mortality risk, while a non-linear association was observed with 14-day and 28-day mortality. Subgroup analysis revealed a significant interaction between milrinone use and heart failure status, with reduced mortality associated with milrinone use only in patients with heart failure. CONCLUSION: Milrinone use appeared to be associated with reduced mortality risk at 7, 14, and 28 days in sepsis patients. This association was linear for 7‑day mortality, but nonlinear and potentially indicative of a threshold effect for 14‑and 28‑day mortality.